BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 32081560)

  • 41. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer.
    Chen X; Zhang J; Ruan W; Huang M; Wang C; Wang H; Jiang Z; Wang S; Liu Z; Liu C; Tan W; Yang J; Chen J; Chen Z; Li X; Zhang X; Xu P; Chen L; Xie R; Zhou Q; Xu S; Irwin DL; Fan JB; Huang J; Lin T
    J Clin Invest; 2020 Dec; 130(12):6278-6289. PubMed ID: 32817589
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Detection of bladder cancer in voided urine samples].
    Thomas A; Renard I; Waltregny D
    Rev Med Liege; 2009; 64 Spec No():9-14. PubMed ID: 20085009
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of Sensitive Urine DNA-Based PENK Methylation Test for Detecting Bladder Cancer in Patients with Hematuria.
    Oh TJ; Lee JY; Seo Y; Woo MA; Lim JS; Na YG; Song KH; Bang BR; Lee JJ; Shin JH; An S
    J Mol Diagn; 2023 Sep; 25(9):646-654. PubMed ID: 37330048
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.
    Critelli R; Fasanelli F; Oderda M; Polidoro S; Assumma MB; Viberti C; Preto M; Gontero P; Cucchiarale G; Lurkin I; Zwarthoff EC; Vineis P; Sacerdote C; Matullo G; Naccarati A
    Oncotarget; 2016 Oct; 7(41):67435-67448. PubMed ID: 27611947
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer.
    Leyh H; Marberger M; Conort P; Sternberg C; Pansadoro V; Pagano F; Bassi P; Boccon-Gibod L; Ravery V; Treiber U; Ishak L
    Eur Urol; 1999 Jan; 35(1):52-6. PubMed ID: 9933795
    [TBL] [Abstract][Full Text] [Related]  

  • 46.
    Rose M; Bringezu S; Godfrey L; Fiedler D; Gaisa NT; Koch M; Bach C; Füssel S; Herr A; Hübner D; Ellinger J; Pfister D; Knüchel R; Wirth MP; Böhme M; Dahl E
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046186
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA.
    Ward DG; Baxter L; Ott S; Gordon NS; Wang J; Patel P; Piechocki K; Silcock L; Sale C; Zeegers MP; Cheng KK; James ND; Bryan RT;
    Eur Urol Oncol; 2023 Feb; 6(1):67-75. PubMed ID: 35410825
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Circulating miR-205: a promising biomarker for the detection and prognosis evaluation of bladder cancer.
    Fang Z; Dai W; Wang X; Chen W; Shen C; Ye G; Li L
    Tumour Biol; 2016 Jun; 37(6):8075-82. PubMed ID: 26715266
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis.
    Wild PJ; Fuchs T; Stoehr R; Zimmermann D; Frigerio S; Padberg B; Steiner I; Zwarthoff EC; Burger M; Denzinger S; Hofstaedter F; Kristiansen G; Hermanns T; Seifert HH; Provenzano M; Sulser T; Roth V; Buhmann JM; Moch H; Hartmann A
    Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1798-806. PubMed ID: 19454613
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Novel Urine-Based Assay for Bladder Cancer Diagnosis: Multi-Institutional Validation Study.
    Davis N; Shtabsky A; Lew S; Rona R; Leibovitch I; Nativ O; Cohen M; Mor Y; Lindner U; Glickman Y; Matzkin H; Tsivian A; Gofrit O; Yossepovitch O
    Eur Urol Focus; 2018 Apr; 4(3):388-394. PubMed ID: 28753799
    [TBL] [Abstract][Full Text] [Related]  

  • 51. UriBLAD: A Urine-Based Gene Expression Assay for Noninvasive Detection of Bladder Cancer.
    Wang Q; Hu L; Ma W; Meng Z; Li P; Zhang X; Wang Y; Lu Y; Sun Y; Wu Y; Ren W; Song K; Chen J; Wu S; Xu Q; Huang D; Zhang D; Shen Y; Ye D
    J Mol Diagn; 2021 Jan; 23(1):61-70. PubMed ID: 33122139
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TERT Promoter Mutations as Simple and Non-Invasive Urinary Biomarkers for the Detection of Urothelial Bladder Cancer in a High-Risk Region.
    Pakmanesh H; Anvari O; Forey N; Weiderpass E; Malekpourafshar R; Iranpour M; Shahesmaeili A; Ahmadi N; Bazrafshan A; Zendehdel K; Kannengiesser C; Ba I; McKay J; Zvereva M; Hosen MI; Sheikh M; Calvez-Kelm FL
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430798
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.
    Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK; Stenzl A; Danella JF; Shepard B; Cline KJ; Williams MB; Montgomery S; David RD; Harris R; Klein EW; Bradford TJ; Wolk FN; Westenfelder KR; Trainer AF; Richardson TA; Egerdie RB; Goldfarb B; Zadra JA; Ge S; Zhao S; Simon IM; Campbell SA; Rhees B; Bates MP; Higuchi RG; Witjes JA
    Eur Urol; 2019 May; 75(5):853-860. PubMed ID: 30553612
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An epigenetic biomarker combination of PCDH17 and POU4F2 detects bladder cancer accurately by methylation analyses of urine sediment DNA in Han Chinese.
    Wang Y; Yu Y; Ye R; Zhang D; Li Q; An D; Fang L; Lin Y; Hou Y; Xu A; Fu Y; Lu W; Chen X; Chen M; Zhang M; Jiang H; Zhang C; Dong P; Li C; Chen J; Yang G; Liu C; Cai Z; Zhou F; Wu S
    Oncotarget; 2016 Jan; 7(3):2754-64. PubMed ID: 26700620
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
    Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
    Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
    [No Abstract]   [Full Text] [Related]  

  • 56. Promoter methylation of DNA damage repair (DDR) genes in human tumor entities:
    Mijnes J; Veeck J; Gaisa NT; Burghardt E; de Ruijter TC; Gostek S; Dahl E; Pfister D; Schmid SC; Knüchel R; Rose M
    Clin Epigenetics; 2018; 10():15. PubMed ID: 29445424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
    Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
    J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Urinary retinoic acid receptor-β2 gene promoter methylation and hyaluronidase activity as noninvasive tests for diagnosis of bladder cancer.
    Eissa S; Zohny SF; Shehata HH; Hegazy MG; Salem AM; Esmat M
    Clin Biochem; 2012 Apr; 45(6):402-7. PubMed ID: 22286019
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance.
    Zhao F; Vesprini D; Liu RSC; Olkhov-Mitsel E; Klotz LH; Loblaw A; Liu SK; Bapat B
    Urol Oncol; 2019 May; 37(5):297.e9-297.e17. PubMed ID: 30777394
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.